MktsMarkets

CNS Pharmaceuticals, Inc.
NASDAQ: CNSPKey statistics
CNSP News
Stories mentioning CNSP from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 3,544 | 3,165 | 2,197 | 1,167 | 3,243 | 1,498 | 4,245 | 1,117 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 4,975 | 5,987 | 3,253 | 2,409 | 4,338 | 3,200 | 5,629 | 2,528 |
| Operating Income (Loss) | (4,975) | (5,987) | (3,253) | (2,409) | (4,338) | (3,200) | (5,629) | (2,528) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (4,937) | (5,957) | (3,218) | (2,375) | (4,301) | (3,176) | (5,606) | (2,531) |
| Earnings Per Share (Basic) | (7.30) | (13.45) | (5.76) | (6.42) | (18.93) | (99.25) | (153.20) | (4,049) |
| Earnings Per Share (Diluted) | (7.30) | (13.45) | (5.76) | (6.42) | (18.93) | (99.25) | (153.20) | (4,049) |
| Weighted Average Shares Outstanding (Basic) | 676.00 | 443.00 | 559.00 | 370.00 | 227.00 | 32.00 | 37.00 | 1.00 |
| Weighted Average Shares Outstanding (Diluted) | 676.00 | 443.00 | 559.00 | 370.00 | 227.00 | 32.00 | 37.00 | 1.00 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CNSP
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a stock listed on the Nasdaq Stock Market under the ticker symbol CNSP. It last traded at $4.51 (Oct 30, 2026, 9:50 AM ET), down 5.5% on the day. That gives CNS Pharmaceuticals a market capitalisation of $6.9M.
Over the past 52 weeks CNSP has traded between $1.90 and $10.54.
For the quarter ended Mar 31, 2026 it reported a net loss of $4.9M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$4.9M |
| Dec 31, 2025 | — | -$6.0M |
| Sep 30, 2025 | — | -$3.2M |
| Jun 30, 2025 | — | -$2.4M |
From CNS Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…